TY - JOUR
T1 - Opportunities and challenges for the cellular immunotherapy sector
T2 - A global landscape of clinical trials
AU - Bonter, Katherine
AU - Breckenridge, Zackariah
AU - Lachance, Silvy
AU - Delisle, Jean Sébastien
AU - Bubela, Tania
N1 - Publisher Copyright:
© 2017 Tania Bubela.
PY - 2017/9
Y1 - 2017/9
N2 - Global investments in cellular immunotherapies reflect their curative potential. Our landscape of clinical trials will aid developers, investors, adopters and payers in planning for adoption and implementation along realistic time horizons. Trend data enable stakeholders to adapt their business models and capacity to bring immunotherapies to the clinic. For cancer, trends suggest a shift from cancer vaccines to adoptive cellular transfer, alongside a focus on solid tumors. Academic centers, mainly in the USA, lead in early-phase clinical trials and target identification; but industry involvement has increased fourfold over the past two decades. Trends indicate an increasingly personalized approach to onco-immunology, which raises challenges for cost-effective manufacturing and delivery models. Overcoming these challenges provides opportunities for innovative biotechnology firms.
AB - Global investments in cellular immunotherapies reflect their curative potential. Our landscape of clinical trials will aid developers, investors, adopters and payers in planning for adoption and implementation along realistic time horizons. Trend data enable stakeholders to adapt their business models and capacity to bring immunotherapies to the clinic. For cancer, trends suggest a shift from cancer vaccines to adoptive cellular transfer, alongside a focus on solid tumors. Academic centers, mainly in the USA, lead in early-phase clinical trials and target identification; but industry involvement has increased fourfold over the past two decades. Trends indicate an increasingly personalized approach to onco-immunology, which raises challenges for cost-effective manufacturing and delivery models. Overcoming these challenges provides opportunities for innovative biotechnology firms.
KW - adoptive cellular therapy
KW - cell therapy
KW - cellular immunotherapy
KW - clinical trial
KW - industry
KW - translational research
UR - http://www.scopus.com/inward/record.url?scp=85031323243&partnerID=8YFLogxK
U2 - 10.2217/rme-2017-0031
DO - 10.2217/rme-2017-0031
M3 - Article
C2 - 28850001
AN - SCOPUS:85031323243
SN - 1746-0751
VL - 12
SP - 623
EP - 636
JO - Regenerative Medicine
JF - Regenerative Medicine
IS - 6
ER -
